Skip to main content
. 2010 Jul 13;103(3):332–339. doi: 10.1038/sj.bjc.6605767

Figure 2.

Figure 2

Mean concentration–time profiles of soluble IGF-IR after intravenous administration of figitumumab and docetaxel every 3 weeks. Concentrations of soluble IGF-IR were expressed as a percentage of individual pre-treatment baseline concentrations. Here, N indicates the number of patients with at least one measurement after the start of cycle 1 dosing.